Triana Biomedicines, a Boston, MA-based biotechnology firm, raised $110M in Sequence A funding.
The spherical was led by Lightspeed Enterprise Companions with participation from Pfizer Ventures, Surveyor Capital and Logos Capital.
The corporate intends to make use of the funds to increase operations and growth efforts.
Triana Biomedicines is constructing a molecular glue discovery platform to control illness targets which can be troublesome to handle with every other modality. Its drug discovery engine is powered by high- decision structural insights, AI and computational instruments, and bespoke chemical libraries. The goal first and rational strategy to molecular glue discovery is presently targeted on inducing or enhancing the degradation of high-profile most cancers targets.
The corporate is led by Dr. Patrick Trojer, President & CEO, Dr. Jesse Chen, CTO and co-founder, Dr. Jean-Christophe Harmange, CSO, and Dr. Kathleen Seyb, SVP of Biology.